HIPAA Alert: Potential Data Breach Learn More

Close this search box.

find a clinical trial

If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.

34 Clinical Trials
Leukemia NA Accepting Patients
nct/study# NCT03258931 / ARO-021

Phase III Randomized Study Of Crenolanib Versus Midostaurin Administered Following Induction Chemotherapy And Consolidation Therapy In Actively Diagnosed Subjects With FLT3 Mutated Acute Myeloid Leukemia

Learn More
Leukemia Phase I Accepting Patients
nct/study# NCT04075747 / JZP025-101

V-FAST: A Phase 1b Master Trial To Investigate CPX-351 Combined With Various Targeted Agents In Subjects With Previously Untreated Acute Myeloid Leukemia

Learn More
Leukemia Phase III Accepting Patients
nct/study# NCT03589326 / PONATINIB-3001

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered In Combination With Reduced-Intensity Chemotherapy, In Patients With Actively Diagnosed Philadelphia Chromosome?Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Learn More
Leukemia Phase II Active
nct/study# NA / BST004

A Phase 2, Open Label, Single Arm, Multi‐Center Study To Assess The Efficacy And Safety Of BST‐236 As A Single Agent In Adults Unfit For Intensive Chemotherapy With Relapsed Or Refractory Acute Myeloid Leukemia Or Higher-Risk Myelodysplastic Syndrome?

Learn More
Leukemia Phase II Active
nct/study# NA / SY-1425-202

Phase II RARA(+) Actively Diagnosed/Untreated AML Study With Venetoclax/Azacitidine And SY-1425 With The Primary Objective To Characterize The Safety And Tolerability Of The Triplet Regimen.

Learn More
Leukemia Phase III Accepting Patients
nct/study# NCT02631070 / ACE-536-MDS-002

A Phase 3, Open-Label, Randomized Study To Compare The Efficacy And Safety Of Luspatercept (ACE-536) Versus Epoetin Alfa For The Treatment Of Anemia Due To IPSS-R Very Low, Low Or Intermediate Risk Myelodysplastic Syndromes (MDS) In ESA Naïve Subjects Who Require Red Blood Cell Transfusions

Learn More

we are here for you

For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.

Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.